Endo Pharmaceuticals Holdings Earnings: Here’s Why Investors are Ambivalent Now
Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP) delivered a profit and met Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company.
Endo Pharmaceuticals Holdings Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased 25.29% to $1.09 in the quarter versus EPS of $0.87 in the year-earlier quarter.
Revenue: Rose 2.59% to $708.5 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Endo Pharmaceuticals Holdings Inc. reported adjusted EPS income of $1.09 per share. By that measure, the company missed the mean analyst estimate of $1.09. It missed the average revenue estimate of $739.99 million.
Quoting Management: “2013 is a year of transition for Endo as we begin to manage the entry of generic competition for LIDODERM® and navigate through the headwinds that we have faced recently, including those with OPANA® ER. I continue to be very optimistic about the future of Endo,” said Rajiv De Silva, president and CEO of Endo. “Since joining the company I have focused on assessing our current strategy and operations with a view to identifying our best opportunities for growth and improving profitability. I look forward to sharing these plans in the months ahead.”
Key Stats (on next page)…